EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

SARS‐CoV‐2 antibody dynamics over time and risk factors associated with infection and long COVID‐19 symptoms in large working environments

Cecilie Bo Hansen iD, Kristina Dvoncova, Laura Pérez-Alós, Kamille Fogh, Johannes Roth Madsen iD, Caroline Hartwell Garred, Ida Jarlhelt, Pernille Brok Nielsen, Steffan Svejgaard Petersen, Charlotte Gandsø Fjordager, Klara Tølbøll Lauritsen, Linda Hilsted und 4 weitere

Journal of Internal Medicine · 2023

DOI: 10.1111/joim.13637 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Internal Medicine, 2023. Verfasst von Cecilie Bo Hansen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmar…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Carlsbergfondet, Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Factors influencing SARS‐CoV‐2 antibody dynamics, transmission, waning and long COVID‐19 symptomatology are still not fully understood.

Methods

In the Danish section of the Novo Nordisk Group, we performed a prospective seroepidemiological study during the first and second waves of the COVID‐19 pandemic. All employees and their household members (>18 years) were invited to participate in a baseline (June–August 2020), 6‐month follow‐up (December 2020–January 2021), and 12‐month follow‐up (August 2021) sampling. In total, 18,614 accepted and provided at least one blood sample and completed a questionnaire regarding socioeconomic background, health status, previous SARS‐CoV‐2 infection, and persistent symptoms. Total antibody and specific IgM, IgG and IgA levels against recombinant receptor binding domain were tested.

Results

At baseline, the SARS‐CoV‐2‐antibody seroprevalence was 3.9%. At 6‐month follow‐up, the seroprevalence was 9.1%, while at 12‐month follow‐up, the seroprevalence was 94.4% (after the vaccine roll‐out). Male sex and younger age (18–40 years) were significant risk factors for seropositivity. From baseline to the 6‐month sampling, we observed a substantial waning of IgM, IgG and IgA levels ( p < 0.001), regardless of age, sex and initial antibody level. An increased antibody level was found in individuals infected prior to vaccination compared to vaccinated infection naïves ( p < 0.0001). Approximately a third of the seropositive individuals reported one or more persistent COVID‐19 symptoms, with anosmia and/or ageusia (17.5%) and fatigue (15.3%) being the most prevalent.

Conclusion

The study provides a comprehensive insight into SARS‐CoV‐2 antibody seroprevalence following infection and vaccination, waning, persistent COVID‐19 symptomatology and risk factors for seropositivity in large working environments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansMaleAdolescentYoung AdultAdultPandemicsPost-Acute COVID-19 SyndromeProspective StudiesSARS-CoV-2Seroepidemiologic StudiesWorking ConditionsAntibodies, ViralRisk FactorsImmunoglobulin AImmunoglobulin GImmunoglobulin M

Stichwörter der Autor:innen

SARS-CoV-2antibodyinfectionlong COVIDtransmissionwaningworking environment

Substanzen

Antibodies, ViralImmunoglobulin AImmunoglobulin GImmunoglobulin M

Autor:innen und Institutionen

  • Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Emergency Medicine and Cardiology, Herlev and Gentofte Hospital, Herlev, Denmark.
  • Novo Nordisk A/S, Måløv, Denmark.
  • Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • The National Biobank, Statens Serum Institut, Copenhagen, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Cecilie Bo Hansen, Johannes Roth Madsen, Kasper Karmark Iversen, Peter Garred

Förderung

  • Carlsbergfondet
  • Novo Nordisk Fonden

Zitieren

APA

Hansen, C. B., Dvoncova, K., Pérez-Alós, L., Fogh, K., Madsen, J. R., Garred, C. H., Jarlhelt, I., Nielsen, P. B., Petersen, S. S., Fjordager, C. G., Lauritsen, K. T., Hilsted, L., Boding, L., Iversen, K. K., Hyveled, L., & Garred, P. (2023). SARS‐CoV‐2 antibody dynamics over time and risk factors associated with infection and long COVID‐19 symptoms in large working environments. Journal of Internal Medicine. https://doi.org/10.1111/joim.13637

Vancouver

Hansen CB, Dvoncova K, Pérez-Alós L, Fogh K, Madsen JR, Garred CH, et al. SARS‐CoV‐2 antibody dynamics over time and risk factors associated with infection and long COVID‐19 symptoms in large working environments. Journal of Internal Medicine. 2023. doi:10.1111/joim.13637

BibTeX
@article{Hansen2023,
  author = {Hansen, Cecilie Bo and Dvoncova, Kristina and Pérez-Alós, Laura and Fogh, Kamille and Madsen, Johannes Roth and Garred, Caroline Hartwell and Jarlhelt, Ida and Nielsen, Pernille Brok and Petersen, Steffan Svejgaard and Fjordager, Charlotte Gandsø and Lauritsen, Klara Tølbøll and Hilsted, Linda and Boding, Lasse and Iversen, Kasper Karmark and Hyveled, Liselotte and Garred, Peter},
  title = {SARS‐CoV‐2 antibody dynamics over time and risk factors associated with infection and long COVID‐19 symptoms in large working environments},
  journal = {Journal of Internal Medicine},
  year = {2023},
  doi = {10.1111/joim.13637}
}
Kostenlos starten →